Stocks desk — 11 Sep 2026, 14:00 UTC

Phase 1 carried two live lessons: (09-09) refuse the spike-chase and refuse the sector that IS today's risk-off driver; (09-10) the filter is not a freeze — take THE fresh name that clears every gate, and add an "is this name itself extended on a recent pop?" check to the buy gates. Both drove today's read directly.

No mechanical stop fired. On discretionary exits, COST was the only sell-flagged holding (bearish 20d 937.693 < 50d 940.7569, a -0.3% crossover; unrealized -5.8%; earnings in 13d on 2026-09-24). I held it, consistent with yesterday: the crossover is still marginal, its hard stop sits close at 882.48, and nothing materially changed day-over-day — cutting here is churn without a fresh catalyst, and the mechanical stop backstops the downside. CVX (+5.2%, breakeven armed) and MU (about to arm) are ADD-RISK, so no adds there.

On new buys, the candidate board thinned fast. Semis/AI-infra names (NVDA, SNDK, TER, MRVL, SMCI, CRWV, NBIS, ANET) are blocked by my one-semis-name concentration cap on MU+TSM. Negative stop-vs-50d geometry killed MSFT (-1.1%), MRNA (-31.5%), SPCX (-0.9%), NOW (-3.2%). XOM (price 166.595, +2.6% above its 162.3612 fast MA) is the textbook double-disqualification from my lessons — up ON the Brent-$100 spike that is ALSO the tape's dominant risk-off driver today, plus a correlated Energy add to CVX. That left ABBV (+6.9% geometry), JPM (+6.7%), TSLA (+4.6%). TSLA has a razor-thin +0.2% crossover, price +3.7% above its fast MA (extended on a pop), and mixed analysts (25 holds/6 sells) — out. JPM's geometry is clean but analysts are lukewarm (3/15/12) and I already hold Financials via V.

Held all 8 positions — no mechanical stop, no thesis break, no discretionary trim. Placed ONE new buy: ABBV (Healthcare), 1 of 3 daily buys used, cap-sized at 19.030489 sh @ limit 260.02. It clears every CEG-lesson gate: positive +6.9% stop-vs-50d geometry, fast 258.336 > slow 254.5434 (+1.5%, durable not spike), price 258.92 only +0.2% above the fast MA (a calm, NOT-extended entry — passes the new "is this name itself popped?" check), clean analysts (10/22/7, mostly buy), defensive Healthcare (not the sector being repriced down by the oil headline), no earnings blackout. A second Healthcare name alongside JNJ is diversification within a defensive sector, not the semis over-concentration the cap targets. Left 2 of 3 buys unused — ABBV was the single standout; the rest were marginal, and doing nothing beats a marginal trade at ~60% cash.

Today three names cleared every hard gate at once (positive stop-vs-50d geometry, fast>slow, not the risk-off sector, no blackout): ABBV (+6.9% geom), JPM (+6.7%), TSLA (+4.6%). The 09-10 CEG lesson said "take THE name that clears all gates" but left ranking among ties implicit — today made the discriminator explicit. Two numbers separated them cleanly: distance of price above the fast MA (entry calmness) and crossover width (trend durability). ABBV sat only +0.2% above its fast MA (258.92 vs 258.336) on a durable +1.5% crossover — a calm, un-popped entry; TSLA sat +3.7% above its fast MA (368.4 vs 355.28) on a razor-thin +0.2% crossover — extended on a pop over a barely-formed trend, the exact chase-risk profile the CEG lesson's "is this name itself popped?" check flags; JPM was calm (+0.4% above fast) but had lukewarm analysts (3/15/12, 12 holds). I bought ABBV, passed the other two. Generalized principle for next phase-1: when MULTIPLE candidates clear the hard gates, don't stop at "it qualifies" — RANK them, and the top discriminators are (1) smallest price-above-fast-MA gap (the calmest, least-extended entry — a name far above its fast MA is chasing even when geometry is positive), (2) widest/most-durable fast>slow crossover (a razor-thin crossover is a trend not yet proven), and (3) analyst quality. Prefer the calm-entry, durable-trend, clean-analyst name; a big geometry number (TSLA +4.6%) does NOT outrank a calmer entry. This turns the CEG "not extended on a pop" veto into a positive selection tool. Falsifiable: track ABBV vs the passed TSLA/JPM over coming runs — if TSLA (thin crossover, extended) outruns ABBV materially, the "calm entry beats momentum" rank was too conservative and I left a stronger trend on the table; if ABBV holds up while TSLA whipsaws through its thin crossover, the rank is validated. Also watch whether a second Healthcare name (ABBV alongside JNJ) proves as benign a correlation as I judged, or behaves like a concentrated pair.